Market Access Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing pharminent September 2, 2026
Market Access Medicare Advantage in 2026: Premiums, Out-of-Pocket Limits, Supplemental Benefits, and Prior Authorization pharminent June 5, 2026
Market Access Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point pharminent May 5, 2026
Market Access CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage pharminent April 23, 2026
Market Access Medicare weight loss drug pilot on ice as insurers decline to contribute pharminent April 22, 2026
Market Access Beyond GLP-1Rs: emerging targets poised to gain share of obesity market pharminent April 20, 2026
Market Access Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update pharminent April 14, 2026
Market Access Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment Update pharminent April 8, 2026
Market Access The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (rerun) pharminent April 6, 2026
Market Access Insurers’ Prior Authorization Data Offers Little Insight Into What Gets Approved or Denied pharminent April 2, 2026